Drugs / Huaiqihuang Granule
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05772871 | Apr 2023 → Sep 2025 | nephrotic syndrome | Jianhua Zhou | Unknown | No outcome recorded |
| Phase 4 | NCT03201848 | Nov 2017 → Oct 2023 | thrombocytopenia due to immune destruction | Qidong Gaitianli Medicines Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huaiqihuang Granule | “Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day;” NCT05772871 ↗ |